Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Hemangiosarcoma × avelumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Transitional Cell 11 Breast Neoplasms 11 Urinary Bladder Neoplasms 10 Neoplasm Metastasis 10 Carcinoma, Merkel Cell 8 Neoplasms 7 Colorectal Neoplasms 7 Carcinoma, Renal Cell 7 Head and Neck Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Squamous Cell Carcinoma of Head and Neck 4 Neuroendocrine Tumors 4 Triple Negative Breast Neoplasms 3 Skin Neoplasms 3 Prostatic Neoplasms 3 Leukemia, Myeloid, Acute 3 Glioblastoma 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Neuroendocrine 3 Carcinoma, Hepatocellular 3 Urethral Neoplasms 2 Ureteral Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Penile Neoplasms 2 Pancreatic Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 Neoplasm, Residual 2 Mesothelioma, Malignant 2

Interventions

Paclitaxel 6 Doxorubicin 5 pembrolizumab 4 pazopanib 4 Gemcitabine 4 durvalumab 3 Radiotherapy 3 Propranolol 3 Docetaxel 3 Surveys and Questionnaires 2 Sunitinib 2 Standard of Care 2 Nivolumab 2 Ifosfamide 2 Bevacizumab 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 tremelimumab 1 trebananib 1 trastuzumab duocarmazine 1 talazoparib 1 spartalizumab 1 sintilimab 1 selinexor 1 sarilumab 1 ribociclib 1 regorafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03512834 2018-07-11

ASAP

Dong-A University Hospital

Phase 2 Unknown

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡